Dialysis-Related Amyloidosis Treatment Act of 2025

This bill would require Medicare to cover and pay for treatments for dialysis-related amyloidosis. It defines these treatments as FDA‑approved items or services given in dialysis facilities, plus any supplies or services needed to deliver the treatment. It also says these treatments are separate from the usual “renal dialysis services” bundle, so they can be paid for on their own. The changes take effect as soon as the law is enacted.

Key points:

• Who is affected: People on Medicare who get dialysis and have dialysis‑related amyloidosis; dialysis facilities that provide their care.
• What changes: Medicare must cover and pay for FDA‑approved treatments for this condition, including necessary related supplies and services; these payments are made separately from the standard dialysis bundle.
• When: Immediately upon enactment.